Methuselah Funds - Investor Profile and Portfolio

Turn Biotechnologies is reprogramming cells to reverse aging process and treat age-related diseases. The company is engineering aged cells for tissue regeneration and self-renewal, reduction in pro-inflammatory signaling and re-engagement of canonical intracellular nutrient regulation pathways in osteoarthritis tissues.

Developer of genetically targeted intervention therapy for age-related diseases. Its technology is based on removing the cells that have entered a non-dividing condition and turns into senescent (zombie) cells. These cells secrete molecules that cause inflammation leading to a large number of age-related diseases.

OncoSenX is a developer of lipid nanoparticles and plasmid DNA for treating cancer. The company has developed the patented lipid nanoparticle (LNP) used for transfecting and delivering the DNA plasmid to cancer cells. The company focuses on inducing apoptosis in the cancer cells via caspase 9 by the use of DNA plasmid which codes for a death protein inside the transcriptionally active for p53 cancer cells.

Developing nerve-regenerating treatments for peripheral neuropathy, improving patient lives. The company focuses on creating disease-modifying treatments for this widespread condition, impacting a significant portion of the global population. They advance scientific breakthroughs from initial discovery and preclinical validation through rigorous clinical trials, aiming for commercialization and partnerships to deliver treatments worldwide. Their process involves identifying promising scientific advancements, guiding innovations through regulatory testing, and bringing approved treatments to patients through commercialization, licensing, and collaboration. The company is dedicated to addressing the unmet needs of individuals burdened by peripheral neuropathy, offering hope for nerve growth and regeneration.